Butterfly Network (BFLY) Q1 2026: Embedded Revenue Jumps 147% as Platform Leverage Emerges
Butterfly Network’s Q1 2026 marked a strategic inflection as embedded and AI-driven software revenues accelerated, validating the platform’s leverage and expanding its addressable market. With FDA-cleared AI tools and a robust embedded partnership pipeline, Butterfly is evolving from a device-focused business to a multi-engine digital health platform. The company’s reaffirmed guidance signals confidence in scaling new revenue streams while maintaining disciplined investment in innovation and operational efficiency.
Summary
- Embedded Platform Surge: Embedded business gains traction, signaling Butterfly’s shift beyond device sales.
- AI-Driven Adoption: FDA-cleared tools and Compass AI contracts accelerate enterprise and global expansion.
- Guidance Confidence: Management signals upside from new partnerships and home care pilots entering commercial phase.
Business Overview
Butterfly Network develops and commercializes semiconductor-based handheld ultrasound devices, leveraging digital imaging and artificial intelligence (AI) to deliver point-of-care diagnostics. The company monetizes through probe and software sales (core business), enterprise AI solutions (Compass AI), platform partnerships (Butterfly Garden), and embedded technology licensing to third parties (Butterfly Embedded). Major segments include U.S. health, international, veterinary, and an emerging home and community care channel.
Performance Analysis
Q1 2026 delivered a robust 25% revenue increase year-over-year, with the embedded segment (Butterfly Embedded, technology licensing and chip sales) growing 147% and now contributing 22% of total revenue. The core business, which encompasses probe sales and associated software, advanced 10% as higher-margin IQ3 device sales offset a decline in lower-priced IQ Plus units. Gross margin expanded to 69%, up from 63% last year, driven by favorable product mix and embedded revenue contribution.
Operating discipline was evident as adjusted EBITDA loss narrowed by 32%, and cash burn improved despite increased investment in innovation and market expansion. International growth tracked at 23% YoY, with U.S. health and veterinary channels showing resilience even in a seasonally slower quarter. The company’s balance sheet remains strong, providing capacity for continued R&D and commercial scaling.
- Embedded Revenue Inflection: Butterfly Embedded revenue surge reflects early success in platform licensing and new market creation.
- Gross Margin Expansion: Higher IQ3 mix and embedded contributions drove a 9-point YoY margin lift, underscoring operational leverage.
- Enterprise Pipeline Build: Compass AI’s first seven-figure contract and a sharply rising pipeline signal momentum in enterprise software adoption.
The quarter’s performance validates Butterfly’s thesis that digital, AI-powered imaging can unlock both new clinical use cases and scalable, recurring revenue streams beyond traditional device sales.
Executive Commentary
"We are living through a profound moment of technological acceleration, one that healthcare has been waiting for, the merge of intelligence with the human body through smart ultrasound form factors that can live with every person everywhere."
Joe DeVivo, Chairman and Chief Executive Officer
"Growth in probe sales of 5% and an increase in the mix of IQ3 devices driving an 11% improvement in ASP year over year, the expansion of the Butterfly Garden platform, as well as the inclusion of the GA tool in our latest software update, execution of a large seven-figure TCV Compass AI contract with a growing pipeline in this area that Joe mentioned up front, and the expected commercial launch in an initial state with a major U.S. direct care provider to support in-person, virtual, and in-home healthcare services."
John Doherty, Chief Financial Officer
Strategic Positioning
1. Embedded Platform: Unlocking New Markets
Butterfly Embedded, the company’s technology licensing and chip sales arm, is rapidly becoming a second growth engine. The addition of new partners—now nine and expected to surpass ten mid-year—brings Butterfly’s programmable ultrasound-on-chip architecture into adjacent verticals such as brain-computer interfaces, robotics, pharma, and wearables. Each new partner represents a potential new market segment, with some deals structured to deliver near-term financial impact similar to the recent Mid Journey partnership.
2. AI and Enterprise Software Expansion
The FDA-cleared gestational age (GA) AI tool, built on deep learning and deployed via cloud-based updates, demonstrates Butterfly’s ability to deliver advanced diagnostics at scale. The Compass AI platform is gaining enterprise traction, with a sharply increased pipeline and the first seven-figure contract signed, signaling the start of multi-year, recurring software revenue streams. The Butterfly Garden, a third-party developer ecosystem, now features 30 partners and is poised to become the industry’s largest AI-powered ultrasound application library.
3. Home and Community Care: Pilot to Commercialization
Butterfly Home and Community Care, a new channel focused on enabling at-risk providers and nurses to deliver bedside diagnostics, is set to sign its first commercial agreement in H1 and launch statewide in Q3. This model leverages AI to empower non-specialists and aims to reduce hospital admissions, with expansion into additional states targeted for 2027. Early feasibility pilots demonstrated meaningful cost and care improvements, supporting the commercial case for broader rollout.
4. Product Innovation and Regulatory Positioning
Butterfly’s roadmap includes a next-generation probe launching in early 2027 and continued regulatory advocacy in the EU to accelerate the shift from legacy piezoelectric to digital ultrasound. The company’s architecture allows rapid deployment of AI features and supports new form factors, including wearables via embedded partners, further broadening the addressable market.
Key Considerations
Butterfly’s Q1 results signal a transition from a single-product company to a multi-engine digital health platform. The interplay between device, software, and embedded licensing is beginning to create compounding network effects and operational leverage.
Key Considerations:
- Embedded Leverage Emergence: Platform licensing and chip sales are now a material contributor, with the potential for large, lumpy deals and recurring revenue as new partners scale.
- AI-Driven Regulatory Moat: FDA clearance of the GA tool sets a high bar for competitors, enabling Butterfly to rapidly deploy new AI features and build trust with global health authorities.
- Enterprise and Education Expansion: Medical school one-to-one programs and enterprise contracts are accelerating, with Q2 expected to be the largest ever for educational channel sales.
- Home Care Commercialization: Initial state-wide launch in 2026 will be a key proof point for the viability and scalability of in-home AI-powered diagnostics.
- Operational Discipline: Margin and EBITDA improvements reflect disciplined capital allocation, even as the company invests in long-term growth engines.
Risks
Butterfly faces execution risk in scaling embedded partnerships and commercializing home care at pace, as well as potential delays in regulatory or partner-driven adoption cycles. Macroeconomic factors and tariffs remain minor headwinds, but the company’s exposure to global supply chain and regulatory shifts could impact results. The shift toward multi-segment reliance introduces complexity and potential for uneven revenue recognition, especially as large embedded deals may be lumpy and timing-dependent.
Forward Outlook
For Q2 2026, Butterfly guided to:
- Revenue of $27 million to $31 million, representing 24% YoY growth at the midpoint
- Adjusted EBITDA loss of $6 million to $8 million
For full-year 2026, management reaffirmed guidance:
- Revenue of $117 million to $121 million (20% to 24% YoY growth)
- Adjusted EBITDA loss of $21 million to $25 million
Management highlighted several factors that inform the outlook:
- Pipeline visibility supports confidence in core and embedded revenue attainment
- Potential upside from new embedded deals and home care commercialization not fully embedded in guidance
Takeaways
Butterfly’s Q1 2026 demonstrates the emergence of a multi-engine platform with upside from embedded technology, AI-driven software, and home care innovation.
- Embedded Platform Scaling: Early embedded deals validate the technology licensing model, with upside as new partners come online and mature into commercial deployment.
- AI and Enterprise Momentum: FDA-cleared tools and Compass AI contracts are driving adoption and expanding the company’s competitive moat in both developed and emerging markets.
- Home Care Proof Point: The transition from pilot to commercial launch in home and community care will be a key catalyst for Butterfly’s next phase of growth, with state-by-state expansion targeted for 2027.
Conclusion
Butterfly Network’s Q1 results highlight a pivotal shift from hardware-centric growth to a diversified platform model, with embedded and AI-driven revenues gaining critical mass. The company’s disciplined execution, expanding regulatory moat, and increasing leverage from partnerships position it for sustained multi-year growth and market leadership in digital health imaging.
Industry Read-Through
Butterfly’s accelerating embedded and AI software revenue signals a broader industry shift toward platform-based medical device models, where cloud connectivity, AI, and programmable hardware enable recurring, high-margin growth. The FDA’s public endorsement of AI tools sets a precedent for regulatory rigor and speed, benefiting companies with robust clinical validation and data pipelines. The emergence of home-based diagnostics and the integration of ultrasound into wearables and adjacent devices suggest that the boundary between traditional imaging, remote care, and digital therapeutics will continue to blur. Competitors in imaging, digital health, and semiconductor-enabled medical devices will need to respond to increasing customer expectations for intelligent, adaptive, and seamlessly integrated solutions.